全内技术联合骨髓抽吸物、脱矿骨基质及缝线加强的股四头肌腱前交叉韧带重建术后高活动恢复率与低再断裂率
简介
该研究回顾性分析了98例采用全内技术、股四头肌腱自体移植物联合骨髓抽吸浓缩物、脱矿骨基质及缝线带增强的ACL重建患者，平均随访3.4年。结果显示91.8%的患者重返伤前活动水平，移植物再撕裂率仅3.1%，IKDC和ACL-RSI评分分别为84.0和93.4。提示该复合增强技术可获得良好的早期重返运动率和较低的失败率。
英文摘要
PURPOSE: To evaluate clinical outcomes of anterior cruciate ligament reconstruction (ACLR) using a quadriceps tendon autograft (QTA) with adjunctive bone marrow aspirate concentrate, demineralized bone matrix, and suture tape augmentation. METHODS: A retrospective review was conducted using a prospectively maintained registry of patients who underwent all-inside ACLR with QTA, adjunctive bone marrow aspirate concentrate, demineralized bone matrix, and suture tape augmentation between July 2018 and October 2022 at a single institution. Patients with less than a 2-year follow-up were excluded. A telephone survey assessed return to preinjury activity level, and patient-reported outcomes were collected, including the International Knee Documentation Committee subjective score, ACL Return to Sport after Injury score, and Visual Analog Scale for pain. Complications such as graft rerupture and total reoperations were also recorded. RESULTS: One hundred twenty patients (81%) received QTA ACLR, with 98 (81.7%) completing ≥2-year follow-up (37 female, 61 male; mean age 19.4 years, range 15-32). Mean follow-up was 3.4 years (range, 2.0-5.9). All patients were cleared for full activity at 6 months postoperatively. At the time of telephone follow-up, 90 patients (91.8%) reported they had returned to their preinjury activity levels. In all 98 patients, mean International Knee Documentation Committee and ACL Return to Sport after Injury scores were 84.0 ± 7.3 and 93.4 ± 17.2, respectively. There were 3 graft reruptures (3.1%) and 9 contralateral ACL tears (9.2%). CONCLUSIONS: All-inside ACLR with QTA, adjunctive bone marrow aspirate concentrate, demineralized bone matrix, and suture tape augmentation showed high rates of return to preinjury activity and low graft rerupture rates at a minimum of 2 years of follow-up. LEVEL OF EVIDENCE: Level IV, retrospective therapeutic case series.